Matthew Harrison
Stock Analyst at Morgan Stanley
(3.38)
# 1,043
Out of 4,435 analysts
506
Total ratings
47.29%
Success rate
2.66%
Average return
Main Sectors:
63 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $515 → $510 | $371.02 | +37.46% | 13 | May 28, 2024 | |
| INSM Insmed | Maintains: Overweight | $40 → $43 | $55.05 | -21.89% | 8 | May 10, 2024 | |
| EDIT Editas Medicine | Upgrades: Equal-Weight | $7 | $5.20 | +34.62% | 11 | May 9, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $80 → $78 | $64.27 | +21.36% | 24 | Apr 26, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $112 | $75.07 | +49.19% | 17 | Apr 26, 2024 | |
| PHVS Pharvaris | Maintains: Overweight | $34 | $18.96 | +79.32% | 14 | Apr 22, 2024 | |
| GMAB Genmab | Maintains: Underweight | $32 | $28.20 | +13.48% | 20 | Mar 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,104 → $1,115 | $980.16 | +13.76% | 29 | Mar 13, 2024 | |
| BIIB Biogen | Maintains: Overweight | $361 → $373 | $224.94 | +65.82% | 32 | Nov 10, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $359 → $364 | $455.34 | -20.06% | 14 | Nov 8, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Overweight | $55 → $38 | $11.88 | +219.87% | 3 | Nov 7, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Overweight | $42 → $38 | $40.74 | -6.73% | 6 | Nov 2, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $183 → $146 | $129.86 | +12.43% | 26 | Oct 31, 2023 | |
| CNTA Centessa Pharmaceuticals | Upgrades: Equal-Weight | $4 → $8 | $8.63 | -7.30% | 8 | Oct 26, 2023 | |
| BGNE BeiGene | Maintains: Overweight | $321 → $319 | $148.85 | +114.31% | 14 | Aug 29, 2023 | |
| IOBT IO Biotech | Maintains: Overweight | $11 → $7 | $1.18 | +493.22% | 3 | Aug 15, 2023 | |
| PRME Prime Medicine | Maintains: Equal-Weight | $21 → $19 | $6.48 | +193.21% | 3 | Aug 14, 2023 | |
| TNYA Tenaya Therapeutics | Maintains: Overweight | $13 → $14 | $4.21 | +232.54% | 4 | Aug 10, 2023 | |
| ALEC Alector | Reiterates: Equal-Weight | $10 | $4.92 | +103.25% | 6 | Aug 7, 2023 | |
| MRNA Moderna | Maintains: Equal-Weight | $128 → $123 | $142.55 | -13.71% | 19 | Aug 4, 2023 | |
| TSVT 2seventy bio | Downgrades: Equal-Weight | $25 → $13 | $4.23 | +207.33% | 8 | Jul 28, 2023 | |
| LEGN Legend Biotech | Maintains: Overweight | $65 → $85 | $40.01 | +112.45% | 8 | Jul 20, 2023 | |
| BLUE bluebird bio | Reiterates: Underweight | $3 | $0.90 | +232.08% | 17 | Jul 11, 2023 | |
| CMCSA Comcast | Reiterates: Buy | $46 | $40.03 | +14.91% | 1 | Apr 24, 2023 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $61 → $63 | $18.56 | +239.44% | 8 | Apr 12, 2023 | |
| VIGL Vigil Neuroscience | Maintains: Equal-Weight | $12 → $13 | $3.18 | +308.81% | 4 | Mar 27, 2023 | |
| IVVD Invivyd | Maintains: Underweight | $2 → $1 | $1.84 | -45.65% | 3 | Mar 27, 2023 | |
| INVA Innoviva | Maintains: Underweight | $13 → $10 | $15.79 | -36.67% | 8 | Mar 3, 2023 | |
| FULC Fulcrum Therapeutics | Downgrades: Equal-Weight | $27 → $8 | $7.85 | +1.91% | 8 | Feb 28, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $57 → $44 | $27.82 | +58.16% | 16 | Feb 27, 2023 | |
| FUSN Fusion Pharmaceuticals | Maintains: Overweight | $19 → $10 | $21.52 | -53.53% | 3 | Jan 27, 2023 | |
| SANA Sana Biotechnology | Maintains: Overweight | $15 → $13 | $7.50 | +73.33% | 3 | Jan 24, 2023 | |
| LYEL Lyell Immunopharma | Maintains: Equal-Weight | $7 → $4 | $2.77 | +44.40% | 4 | Jan 24, 2023 | |
| BOLT Bolt Biotherapeutics | Maintains: Equal-Weight | $5 → $3 | $0.76 | +296.46% | 4 | Jan 24, 2023 | |
| BNTX BioNTech SE | Maintains: Equal-Weight | $203 → $216 | $100.60 | +114.71% | 8 | Jan 24, 2023 | |
| AVIR Atea Pharmaceuticals | Maintains: Underweight | $7 → $4 | $3.67 | +8.99% | 7 | Jan 24, 2023 | |
| ADCT ADC Therapeutics | Maintains: Equal-Weight | $7 → $5 | $3.43 | +45.77% | 8 | Jan 24, 2023 | |
| ADAG Adagene | Maintains: Overweight | $7 → $5 | $2.80 | +78.57% | 6 | Jan 24, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $178 → $182 | $161.24 | +12.88% | 7 | Dec 6, 2022 | |
| KOD Kodiak Sciences | Maintains: Equal-Weight | $12 → $9 | $3.18 | +183.02% | 9 | Nov 14, 2022 | |
| AKRO Akero Therapeutics | Maintains: Equal-Weight | $30 → $40 | $18.82 | +112.54% | 5 | Nov 7, 2022 | |
| AMGN Amgen | Maintains: Overweight | $279 → $282 | $305.85 | -7.80% | 20 | Nov 4, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $220 → $210 | $148.43 | +41.48% | 7 | Oct 28, 2022 | |
| ALVR AlloVir | Maintains: Overweight | $32 → $27 | $0.75 | +3,476.63% | 5 | Sep 9, 2022 | |
| PFE Pfizer | Maintains: Equal-Weight | $55 → $52 | $28.66 | +81.44% | 5 | May 4, 2022 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $175 → $173 | $146.67 | +17.95% | 3 | Apr 6, 2022 | |
| SAGE Sage Therapeutics | Maintains: Equal-Weight | $61 → $57 | $11.11 | +413.05% | 4 | Mar 10, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $156 → $120 | $40.14 | +198.95% | 5 | Feb 1, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Equal-Weight | $145 → $148 | $35.10 | +321.65% | 9 | Jan 7, 2022 | |
| MRK Merck & Co. | Maintains: Equal-Weight | n/a | $125.54 | - | 4 | Nov 29, 2021 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | n/a | $41.09 | - | 2 | Oct 12, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | n/a | $3.43 | - | 2 | Aug 18, 2021 | |
| RPRX Royalty Pharma | Maintains: Equal-Weight | n/a | $27.41 | - | 1 | Aug 16, 2021 | |
| OGN Organon & Co. | Maintains: Equal-Weight | n/a | $21.33 | - | 1 | Aug 16, 2021 | |
| LLY Eli Lilly | Maintains: Overweight | n/a | $820.34 | - | 1 | Aug 4, 2021 | |
| TV Grupo Televisa, S.A.B. | Initiates: Buy | n/a | $3.33 | - | 1 | Jun 24, 2021 | |
| RGNX REGENXBIO | Maintains: Overweight | n/a | $14.35 | - | 4 | Mar 8, 2021 | |
| HBAN Huntington Bancshares | Maintains: Equal-Weight | n/a | $13.92 | - | 1 | Feb 24, 2021 | |
| UBX Unity Biotechnology | Downgrades: Equal-Weight | n/a | $1.55 | - | 2 | Aug 18, 2020 | |
| EVLO Evelo Biosciences | Downgrades: Equal-Weight | n/a | $0.00 | - | 1 | May 21, 2020 | |
| INCY Incyte | Maintains: Equal-Weight | n/a | $57.79 | - | 1 | Jan 6, 2020 | |
| RDUS Radius Health | Maintains: Overweight | n/a | $17.11 | - | 4 | Oct 11, 2018 | |
| CYTK Cytokinetics | Assumes: Equal-Weight | n/a | $48.51 | - | 4 | Sep 10, 2018 |
argenx SE
May 28, 2024
Maintains: Overweight
Price Target: $515 → $510
Current: $371.02
Upside: +37.46%
Insmed
May 10, 2024
Maintains: Overweight
Price Target: $40 → $43
Current: $55.05
Upside: -21.89%
Editas Medicine
May 9, 2024
Upgrades: Equal-Weight
Price Target: $7
Current: $5.20
Upside: +34.62%
Gilead Sciences
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $80 → $78
Current: $64.27
Upside: +21.36%
BioMarin Pharmaceutical
Apr 26, 2024
Maintains: Overweight
Price Target: $115 → $112
Current: $75.07
Upside: +49.19%
Pharvaris
Apr 22, 2024
Maintains: Overweight
Price Target: $34
Current: $18.96
Upside: +79.32%
Genmab
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $28.20
Upside: +13.48%
Regeneron Pharmaceuticals
Mar 13, 2024
Maintains: Overweight
Price Target: $1,104 → $1,115
Current: $980.16
Upside: +13.76%
Biogen
Nov 10, 2023
Maintains: Overweight
Price Target: $361 → $373
Current: $224.94
Upside: +65.82%
Vertex Pharmaceuticals
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $359 → $364
Current: $455.34
Upside: -20.06%
Zentalis Pharmaceuticals
Nov 7, 2023
Maintains: Overweight
Price Target: $55 → $38
Current: $11.88
Upside: +219.87%
Cerevel Therapeutics Holdings
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $40.74
Upside: -6.73%
Sarepta Therapeutics
Oct 31, 2023
Maintains: Overweight
Price Target: $183 → $146
Current: $129.86
Upside: +12.43%
Centessa Pharmaceuticals
Oct 26, 2023
Upgrades: Equal-Weight
Price Target: $4 → $8
Current: $8.63
Upside: -7.30%
BeiGene
Aug 29, 2023
Maintains: Overweight
Price Target: $321 → $319
Current: $148.85
Upside: +114.31%
IO Biotech
Aug 15, 2023
Maintains: Overweight
Price Target: $11 → $7
Current: $1.18
Upside: +493.22%
Prime Medicine
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $6.48
Upside: +193.21%
Tenaya Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $13 → $14
Current: $4.21
Upside: +232.54%
Alector
Aug 7, 2023
Reiterates: Equal-Weight
Price Target: $10
Current: $4.92
Upside: +103.25%
Moderna
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $128 → $123
Current: $142.55
Upside: -13.71%
2seventy bio
Jul 28, 2023
Downgrades: Equal-Weight
Price Target: $25 → $13
Current: $4.23
Upside: +207.33%
Legend Biotech
Jul 20, 2023
Maintains: Overweight
Price Target: $65 → $85
Current: $40.01
Upside: +112.45%
bluebird bio
Jul 11, 2023
Reiterates: Underweight
Price Target: $3
Current: $0.90
Upside: +232.08%
Comcast
Apr 24, 2023
Reiterates: Buy
Price Target: $46
Current: $40.03
Upside: +14.91%
Denali Therapeutics
Apr 12, 2023
Maintains: Overweight
Price Target: $61 → $63
Current: $18.56
Upside: +239.44%
Vigil Neuroscience
Mar 27, 2023
Maintains: Equal-Weight
Price Target: $12 → $13
Current: $3.18
Upside: +308.81%
Invivyd
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.84
Upside: -45.65%
Innoviva
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $15.79
Upside: -36.67%
Fulcrum Therapeutics
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $7.85
Upside: +1.91%
Galapagos NV
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $57 → $44
Current: $27.82
Upside: +58.16%
Fusion Pharmaceuticals
Jan 27, 2023
Maintains: Overweight
Price Target: $19 → $10
Current: $21.52
Upside: -53.53%
Sana Biotechnology
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $7.50
Upside: +73.33%
Lyell Immunopharma
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $4
Current: $2.77
Upside: +44.40%
Bolt Biotherapeutics
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $0.76
Upside: +296.46%
BioNTech SE
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $100.60
Upside: +114.71%
Atea Pharmaceuticals
Jan 24, 2023
Maintains: Underweight
Price Target: $7 → $4
Current: $3.67
Upside: +8.99%
ADC Therapeutics
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.43
Upside: +45.77%
Adagene
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $2.80
Upside: +78.57%
AbbVie
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $161.24
Upside: +12.88%
Kodiak Sciences
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $3.18
Upside: +183.02%
Akero Therapeutics
Nov 7, 2022
Maintains: Equal-Weight
Price Target: $30 → $40
Current: $18.82
Upside: +112.54%
Amgen
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $305.85
Upside: -7.80%
Alnylam Pharmaceuticals
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $148.43
Upside: +41.48%
AlloVir
Sep 9, 2022
Maintains: Overweight
Price Target: $32 → $27
Current: $0.75
Upside: +3,476.63%
Pfizer
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $28.66
Upside: +81.44%
Johnson & Johnson
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $146.67
Upside: +17.95%
Sage Therapeutics
Mar 10, 2022
Maintains: Equal-Weight
Price Target: $61 → $57
Current: $11.11
Upside: +413.05%
Ultragenyx Pharmaceutical
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $40.14
Upside: +198.95%
Biohaven Pharmaceutical Holding Company
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $35.10
Upside: +321.65%
Merck & Co.
Nov 29, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $125.54
Upside: -
Bristol-Myers Squibb Company
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $41.09
Upside: -
Taysha Gene Therapies
Aug 18, 2021
Maintains: Overweight
Price Target: n/a
Current: $3.43
Upside: -
Royalty Pharma
Aug 16, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $27.41
Upside: -
Organon & Co.
Aug 16, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $21.33
Upside: -
Eli Lilly
Aug 4, 2021
Maintains: Overweight
Price Target: n/a
Current: $820.34
Upside: -
Grupo Televisa, S.A.B.
Jun 24, 2021
Initiates: Buy
Price Target: n/a
Current: $3.33
Upside: -
REGENXBIO
Mar 8, 2021
Maintains: Overweight
Price Target: n/a
Current: $14.35
Upside: -
Huntington Bancshares
Feb 24, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $13.92
Upside: -
Unity Biotechnology
Aug 18, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $1.55
Upside: -
Evelo Biosciences
May 21, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $0.00
Upside: -
Incyte
Jan 6, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $57.79
Upside: -
Radius Health
Oct 11, 2018
Maintains: Overweight
Price Target: n/a
Current: $17.11
Upside: -
Cytokinetics
Sep 10, 2018
Assumes: Equal-Weight
Price Target: n/a
Current: $48.51
Upside: -